Why 2017 Could Be This Stock's Best Year Yet
Nearly five years ago, Abbott Labs spun off its biopharmaceutical unit into a separate entity. That new company, AbbVie (NYSE: ABBV), enjoyed a tremendous first year, with its share price soaring more than 50% in 2013. However, the following years weren't as great for AbbVie. Until now.
Granted, AbbVie stock isn't up more than 50% year to date at this point. But it's really close to that level. And there's plenty of time remaining in the year. Here's why 2017 could be the stocks's best year yet.
Image source: Getty Images.
Source: Fool.com
Amgen Inc. Stock
€307.50
0.100%
With 25 Buy predictions and not a single Sell prediction Amgen Inc. is an absolute favorite of our community.
However, we have a potential of -1.14% for Amgen Inc. as the target price of 304 € is below the current price of 307.5 €.
